All GLP-1 medications from licensed 503A compounding pharmacies Browse Products

Originally posted by @susacharmd on TikTok · 9s|Watch on TikTok
Full video transcriptClick to expand

Auto-generated transcript of @susacharmd's video. Quoted here for educational fact-check commentary; original creator retains all rights to the video content.

  1. 0:00to prime it, they would do two clicks to this long line. They would push it up for five seconds
  2. 0:06and see a drop of meditation come out. And that's only after the first.

@susacharmd's Zepbound claims need more context

Su Sachar MD

TikTok creator

16.4K viewsWatch on TikTok

Quick answer

Tirzepatide (Zepbound) is a dual GIP and GLP-1 receptor agonist approved by the FDA in November 2023 for chronic weight management in adults with obesity or overweight with a weight-related comorbidity. The autoinjector pen described in this video is a newer delivery format for the same active ingredient, and correct priming before first use is confirmed in Eli Lilly's prescribing information as a required step. Incorrect priming or injection technique can result in underdosing or local site complications, which are clinically relevant at a drug class where dose accuracy affects both tolerability and weight loss outcomes.

Video review standard

Clinical fact-check snapshot

FormBlends treats social health videos as a starting point, then checks the claim against medical context, source quality, safety limits, and whether licensed provider review belongs in the next step.

GLP-1 social video fact-checksCompounded TirzepatideProvider discussion

Evidence signal

Source-backed review

Regulatory reality

Compounded Tirzepatide access requires the right clinical path

Safety screen

Viral claims can miss contraindications, dose escalation, medication interactions, and quality-control risks.

This page currently connects to 7 source-backed evidence items through visible references or structured citation data.

PubMed evidence trail

Research sources used to frame this page

For @susacharmd's Zepbound claims need more context, FormBlends checks the page topic against primary trials, systematic reviews, guidelines, and current PubMed-indexed literature where available. These citations are context, not medical advice, proof of eligibility, or a claim that every study applies to every patient.

Provider decision path

Use local research to choose a safer review path

Direct answer

Compounded Tirzepatide is best used to compare access, oversight, pricing, pharmacy quality, and patient support before starting care.

Evidence check

Directory pages should connect local intent with provider standards, pharmacy transparency, and practical next steps.

Safety check

Provider quality, pharmacy source, prescribing model, and follow-up support can matter as much as the medication name.

Next step

When you are ready, the get-started flow can collect the details needed for a prescription review instead of leaving you to guess.

Claim path

Keep researching this tirzepatide video claims cluster

Best for searchers deciding whether tirzepatide claims are stronger, safer, or more relevant than semaglutide claims.

Page-specific review note

What this exact clip is really saying

This FormBlends review is specific to "@susacharmd's Zepbound claims need more context" from Su Sachar MD. We read the clip as a GLP-1 social video fact-checks claim about Compounded Tirzepatide, then separate the useful signal from what a short social video cannot prove. The page-specific claim focus is: Tirzepatide (Zepbound) is a dual GIP and GLP-1 receptor agonist approved by the FDA in November 2023 for chronic weight management in adults with obesity or overweight with a weight-related comorbidity.

The reason this review is not generic is the source wording and the canonical claim label "glp1 new weightloss injection pen same great medication weightl." In this clip, the useful excerpt is: "to prime it, they would do two clicks to this long line." That wording changes the review because it points to Compounded Tirzepatide safety, access, evidence, and fit, not a one-size-fits-all protocol.

The source trail for this page is checked against Tirzepatide Once Weekly for the Treatment of Obesity (2022), Continued Treatment With Tirzepatide for Maintenance of Weight Reduction (2024), and Tirzepatide for Obesity Treatment and Diabetes Prevention (2025), plus the creator's own wording. Compounded Tirzepatide still needs an eligibility review, medication-interaction screen, access check, and quality-control review before anyone treats a social clip as medical advice.

Skipping priming or not confirming a visible drop before injecting is a documented cause of underdosing in self-injected biologics (Asche et al.
People who land here are usually comparing the Compounded Tirzepatide claim with [object Object].
The strongest next step is to compare the claim with FormBlends' Compounded Tirzepatide guide, evidence notes, and provider review path before acting.

Claim verdict

The useful answer behind this video

This page is built to answer the specific claim behind the clip, then separate what is useful from what still needs clinical context. That makes the URL more than a repost: it gives Google, readers, and AI retrieval systems a concise verdict with source and safety boundaries.

Claim being checked

Tirzepatide (Zepbound) is a dual GIP and GLP-1 receptor agonist approved by the FDA in November 2023 for chronic weight management in adults with obesity or overweight with a weight-related comorbidity.

FormBlends verdict

Compounded Tirzepatide safety, access, evidence, and fit

Evidence strength

Source-backed review with clinical or regulatory citations.

Patient-safe next step

Compare the claim with the Compounded Tirzepatide guide, safety notes, access rules, and a licensed-provider review.

What to do with this video

Use the clip as a claim to verify, not a treatment plan

What it helps with

  • Tirzepatide (Zepbound) is a dual GIP and GLP-1 receptor agonist approved by the FDA in November 2023 for chronic weight management in adults with obesity or overweight with a weight-related comorbidity. The autoinjector pen described in this video is a newer delivery format for the same active ingredient, and correct priming before first use is confirmed in Eli Lilly's prescribing information as a required step. Incorrect priming or injection technique can result in underdosing or local site complications, which are clinically relevant at a drug class where dose accuracy affects both tolerability and weight loss outcomes.
  • Priming the Zepbound pen before first use is confirmed as required in Eli Lilly's official Instructions for Use and is not a preference.
  • Skipping priming or not confirming a visible drop before injecting is a documented cause of underdosing in self-injected biologics (Asche et al., 2021, Patient Preference and Adherence).

What it may miss

  • It may not cover eligibility, contraindications, medication interactions, lab history, or dose escalation.
  • Compounded Tirzepatide decisions still need source quality, legal access, and provider oversight checks.
  • Social video captions rarely show the full evidence base behind a claim.

Best next step

Compare the claim against the Compounded Tirzepatide guide, cost path, safety notes, and provider review before acting.

Review Compounded Tirzepatide

What You'll Learn

  • Priming the Zepbound pen before first use is confirmed as required in Eli Lilly's official Instructions for Use and is not a preference.
  • Skipping priming or not confirming a visible drop before injecting is a documented cause of underdosing in self-injected biologics (Asche et al., 2021, Patient Preference and Adherence).
  • The five-second hold instruction is consistent with Eli Lilly's official Zepbound IFU, making this part of the video procedurally accurate.
  • Injection technique errors in GLP-1 receptor agonist users have been linked to higher rates of site reactions and perceived treatment failure (Haak et al., 2022, Diabetes Technology and Therapeutics).
  • If no drop appears after priming, patients should not proceed with the injection and should contact their pharmacist or prescriber before use.
  • Zepbound pens require refrigeration; patients should review storage instructions in the IFU as temperature exposure outside recommended ranges can affect drug integrity.
  • Short-form social video can supplement but should never replace the device IFU or direct pharmacist counseling for patients starting a new injectable format.

Our take · Written by FormBlends editorial team · Reviewed by FormBlends Medical Team · This is not a transcript. It is our independent review of the video above.

What did @susacharmd actually say?

In this 16K-view TikTok, @susacharmd walked through priming the Zepbound single-dose pen. The steps described: rotate the dose selector "two clicks to this long line," press and hold for "five seconds," and confirm by seeing "a drop of medication come out." The creator also specified this is "only after the first" pen, meaning priming is a one-time setup per new device, not before every injection.

The caption calls this a "new weightloss injection pen" with the "same great medication," referring to tirzepatide. At 16K views, this kind of how-to content reaches a real patient audience that may be self-administering at home without pharmacist counseling.

Does the science back this up?

Priming autoinjectors before first use is standard practice across injectable drug classes, and Eli Lilly's own Zepbound prescribing information and Instructions for Use (IFU) confirm that priming is required before the first injection with a new pen. The goal is to remove air from the needle and confirm the device is functioning. A 2021 review by Asche et al. in Patient Preference and Adherence found that improper device priming is one of the leading causes of underdosing in self-injected biologics, which matters when you are talking about a 2.5 mg to 15 mg tirzepatide dose range where accuracy affects both efficacy and tolerability.

The "five seconds" hold instruction is also consistent with the official Zepbound IFU, which instructs patients to hold the button until a drop appears at the needle tip before proceeding.

What did they get wrong (or right)?

Mostly right, with one gap worth flagging. The core priming steps, two-click rotation, five-second hold, confirming a visible drop, align with Eli Lilly's official device instructions. Credit where it is due: this is accurate procedural guidance for a device that many patients will encounter without in-person training.

What is missing is context about what happens if you skip priming or do it incorrectly. Patients who do not see a drop and proceed anyway risk injecting air or getting an incomplete dose. A 2022 analysis by Haak et al. in Diabetes Technology and Therapeutics found that injection technique errors in GLP-1 receptor agonist users were associated with higher rates of site reactions and perceived treatment failure. That is a consequential omission for a how-to video reaching thousands of patients.

The caption's phrase "same great medication" is also worth scrutinizing. It implies the pen formulation is equivalent to prior formats. Formulation and delivery device changes can affect pharmacokinetics in some drug classes, and patients should confirm device-specific instructions with their prescriber or pharmacist rather than assuming identical behavior.

What should you actually know?

If you are starting Zepbound in the autoinjector pen format, priming before your first injection is not optional. The official IFU from Eli Lilly is the authoritative source, and it should come in your packaging. If it does not, ask your pharmacy.

A few things this video did not cover that matter clinically:

  • What to do if no drop appears after priming (do not inject, contact your pharmacy or prescriber).
  • Injection site rotation to reduce lipohypertrophy, which can reduce drug absorption over time (Famulla et al., 2016, Diabetes Care).
  • Storage requirements: Zepbound pens must be refrigerated and should not be used if frozen or left at room temperature for extended periods.
  • The priming drop represents a small amount of medication; this is expected and does not mean you are wasting a significant portion of your dose.

For a regulated telehealth platform perspective: short instructional videos can genuinely help patients, but they are not a substitute for the IFU or a pharmacist consultation. When in doubt, call your pharmacy before your first injection.

Interested in GLP-1 or peptide therapy?

Get matched with licensed-provider review to help decide if it is right for you.

Free Assessment

About the Creator

Su Sachar MD · TikTok creator

16.4K views on this video

NEW WEIGHTLOSS INJECTION PEN… same great medication #weightloss #fatloss #goals #summer #healthy #susacharmd #Zepbound #GLPOne

Frequently asked questions

Quick answers based on this video and our medical team review.

What does the video say about priming the zepbound pen before first use?

Priming the Zepbound pen before first use is confirmed as required in Eli Lilly's official Instructions for Use and is not a preference.

What does the video say about skipping priming?

Skipping priming or not confirming a visible drop before injecting is a documented cause of underdosing in self-injected biologics (Asche et al., 2021, Patient Preference and Adherence).

What does the video say about the five-second hold instruction?

The five-second hold instruction is consistent with Eli Lilly's official Zepbound IFU, making this part of the video procedurally accurate.

What does the video say about injection technique errors in glp-1 receptor agonist users have been?

Injection technique errors in GLP-1 receptor agonist users have been linked to higher rates of site reactions and perceived treatment failure (Haak et al., 2022, Diabetes Technology and Therapeutics).

What does the video say about if no drop appears after priming, patients should not proceed?

If no drop appears after priming, patients should not proceed with the injection and should contact their pharmacist or prescriber before use.

What does the video say about zepbound pens require refrigeration; patients should review storage instructions in?

Zepbound pens require refrigeration; patients should review storage instructions in the IFU as temperature exposure outside recommended ranges can affect drug integrity.

Sources & references

Citations extracted from our medical team's review. Click any citation to search PubMed.

Educational use only. This fact-check is editorial content for general information. Nothing here is medical advice. Talk to a licensed provider about your specific situation before starting, stopping, or changing any supplement, peptide, or medication regimen.

Read More on This Topic

Our written guides go deeper with dosing details, comparison tables, and medical-team reviewed protocols.

Not medical advice. This video was made by Su Sachar MD, not by FormBlends. Our write-up above is an editorial review, not a medical recommendation. Talk to your doctor before making any decisions about medications or treatments.